Taligen Therapeutics (Aurora, CO) a development stage biotechnology company focused on the treatment of serious inflammatory diseases including asthma, macular degeneration and immune kidney disease closed a $65M Series B financing. Participants include Alta Partners, Clarus Ventures, Sanderling Ventures, Tango and High Country Venture.

Arriva Pharmaceuticals (Alameda, CA) a development stage biotechnology company focused  anti-inflammatory therapies for treating respiratory diseases closed a $6M financing. Participants included Nordic Biotech and MPM Capital.

Vaccinex  (Rochester, NY) a research and development stage antibody platform company focused on oncology and inflammation closed a $25M Series B financing. Participants include Teva Pharmaceuticals, Pan Atlantic Bank & Trust, Biocon and Toronto Investment Group.

Calisotga Pharma (Seattle, WA) a biopharmaceutical company developing multiple compounds selectively targeting the PI3K pathway, a pathway known to be involved in certain cancers and inflammatory diseases closed a $26.2M Series A financing. Participants include Frazier Healthcare Venture, Alta Partners, Three Arch Partners, Amgen Ventures and Lilly Ventures.

ProtAffin Biotechnologie (Austria) is focused on developing novel biotechnology therapeutic products for acute and chronic inflammatory diseases has closed a €4.0M Series A financing. Participants include The Entrepreneurs Fund BV, Aescap Venture Management and Z-Cube.

ChemoCentryx (Mountain View, CA) a developer of drugs for autoimmune diseases, inflammatory diseases and oncology with lead indications for inflammatory bowel disease and multiple sclerosis, closed a $29.9M Series D finanicing. The deal was led by the Glaxo Group Ltd. and was joined by Alta Partners, GIMV, HBM BioVentures and OrbiMed Advisors.

Nitec Pharma (Switzerland) a drug company focused on the treatment of chronic inflammatory diseases with lead indications in Rheumatoid Arthritis and Polymylagia Rheumatica, raised $26M Series B round. The deal was led by NGN Capital other participants included Atlas Venture and Global Life Science Ventures.

Amira Pharmaceuticals (San Diego, CA) drug company focused on inflammatory respitory and cardiovascular disease solutions via the leukotriene and TNF? pathways closed a $25M Series B financing. The deal was led by Novo AS and joined by Avalon Ventures, Prospect Venture Partners and Versant Ventures.

Tragara (San Diego, CA) a pharmaceutical company developing therapies for the treatment of lung cancer and inflammatory diseases closed a $40M Series A round. The financing was led by Domain Associates, ProQuest Investments, Morgenthaler Ventures, Oxford Bioscience Partners and Mitsubishi International Corporation.

Calistoga Pharmaceuticals (Seattle, WA) a drug development startup focused on oncology and inflammation raised a $21M Series A. The deal was led by Frazier Healthcare Ventures and was joined by Alta Partners, Three Arch Partners and Amgen Ventures.